Martin Wald

This inventor holds 5 USPTO granted patents and 3 published patent applications and 3 EPO patents. Top assignee: Merck Patent Gmbh. Active years: 2012-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Martin Wald. Retrieved from https://idiyas.com/inventor/martin-wald

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 (Patent Applications = 3)

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 6.4

ph-index = 1

Forward Citations = 1(Granted Patents)

Company Filing History:

5 out of 3,025

Merck Patent Gmbh

patents

Years Active: 2012-2018

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9975932 - Variants of group 5 allergens of the true grasses having reduced allergeneity due to mutagenesis of proline residues (2018-05-22),

2. 9522938 - Phl p 5a derivatives having reduced allergeneity and retained T-cell reactivity (2016-12-20),

3. 8999348 - Variants of group 6 allergens of the true grasses having reduced allergeneity due to mutagenesis of proline residues (2015-04-07),

4. 8628946 - Phl p 5a derivatives having reduced allergeneity and retained T-cell reactivity (2014-01-14),

5. 8263090 - [object Object] (2012-09-11),

Title: Martin Wald: Innovator in Allergen Research

Introduction

Martin Wald is a prominent inventor based in Hamburg, Germany. He has made significant contributions to the field of allergen research, particularly focusing on reducing allergenicity in grass pollen. With a total of 5 patents, his work is pivotal in developing hypoallergenic variants that can aid in immunotherapy for patients suffering from grass pollen allergies.

Latest Patents

Wald's latest patents include innovative approaches to creating recombinant variants of group 5 allergens of the true grasses. One of his notable inventions is aimed at reducing IgE reactivity while retaining T-lymphocyte reactivity. This invention is crucial for the preparation and use of variants that can be employed in specific immunotherapy for grass pollen allergies. Another significant patent involves Phl p 5a derivatives, which also focus on reducing allergenicity while maintaining essential immune responses.

Career Highlights

Martin Wald is currently associated with Merck Patent GmbH, where he continues to advance his research in allergen variants. His work has garnered attention for its potential to improve the quality of life for individuals with grass pollen allergies. His innovative approaches have positioned him as a key figure in the field of allergen research.

Collaborations

Wald collaborates with notable colleagues, including Oliver Cromwell and Andreas Nandy. Their combined expertise enhances the research and development of hypoallergenic solutions.

Conclusion

Martin Wald's contributions to allergen research are significant and impactful. His innovative patents and collaborations reflect his commitment to improving allergy treatments. His work continues to pave the way for advancements in immunotherapy for grass pollen allergies.

Profile summary based on public USPTO records.